Galantamine is a reversible acetylcholinesterase inhibitor used in the treatment of mild to moderate Alzheimer’s disease. By inhibiting the breakdown of acetylcholine, this alkaloid enhances cholinergic… Read more
![Chemical structure of (4aS,6R,8aS)-6-hydroxy-3-methoxy-11-methyl-4a,5,9,10,11,12-hexahydro-6H-benzo[2,3]benzofuro[4,3-cd]azepine 11-oxide](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F199014-26-1-4aS6R8aS-6-hydroxy-3-methoxy-11-methyl-4a59101112-hexahydro-6H-benzo23benzofuro43-cdazepine-11-oxide.png&w=3840&q=75)
![Chemical structure of 3-Methoxy-11-methyl-4a,5,9,10,11,12-hexahydro-6H-benzo[2,3]benzofuro[4,3-cd]azepin-6-one](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F1668-86-6-3-Methoxy-11-methyl-4a59101112-hexahydro-6H-benzo23benzofuro43-cdazepin-6-one.png&w=3840&q=75)






















Galantamine is a reversible acetylcholinesterase inhibitor used in the treatment of mild to moderate Alzheimer’s disease. By inhibiting the breakdown of acetylcholine, this alkaloid enhances cholinergic neurotransmission to assist in managing cognitive symptoms. This category includes high-quality reference standards for the active pharmaceutical ingredient (API), along with an extensive range of associated compounds required for rigorous pharmaceutical analysis. Laboratories utilize these materials for impurity profiling, method validation, and stability testing, ensuring compliance with regulatory quality control standards. The selection features pharmacopeial and non-pharmacopeial impurities, degradation products—such as those resulting from oxidation or hydrolysis—and a comprehensive suite of stable isotope labelled compounds. These specialized standards are essential for the accurate identification and quantification of related substances in drug development and batch release testing, facilitating precise analytical outcomes in both research and manufacturing environments.